Recent clinical trials have demonstrated a clear survival advantage in advanced head and
neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint blockade …

Background Targeting the immune checkpoint pathway has demonstrated antitumor
cytotoxicity in treatment-refractory head and neck squamous cell carcinoma (HNSC). To …

BACKGROUND Recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma
(HNSCC) is generally an incurable disease, with patients experiencing median survival of …

Head and Neck Squamous Cell Carcinoma (HNSCC) is the 6th most common cancer
globally and commonly presents with locally advanced disease, which has a recurrence rate …

Head and neck squamous cell carcinoma (HNSCC) accounts for more than 600,000 cases
and 380,000 deaths annually worldwide. Although human papillomavirus (HPV)–associated …

Mucosal head and neck squamous cell carcinoma (HNSCC) are the seventh most common
cancer, with approximately 50% of patients living beyond 5 years. Immune checkpoint …

Head and neck squamous carcinoma (HNSCC) is highly infiltrated by immune cells,
including tumor-infiltrating lymphocytes and myeloid lineage cells. In the tumor …

Head and neck squamous cell carcinomas (HNSCCs) are highly aggressive, multi-factorial
tumors in the upper aerodigestive tract affecting more than half a million patients worldwide …

Head and neck squamous cell carcinomas (HNSCCs) arise in the mucosal linings of the
upper aerodigestive tract and are unexpectedly heterogeneous in nature. Classical risk …

Cancers progress when the immune system fails to identify and eliminate malignant cells.
Recognition of this, combined with advances in tumor immunology, has allowed …